Granules India (532482) Stock Overview
Manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for 532482 from our risk checks.
532482 Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Granules India Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹492.80 |
52 Week High | ₹724.55 |
52 Week Low | ₹412.05 |
Beta | 0.092 |
1 Month Change | -6.98% |
3 Month Change | 12.82% |
1 Year Change | -6.23% |
3 Year Change | 76.44% |
5 Year Change | 110.42% |
Change since IPO | 16,057.38% |
Recent News & Updates
Shareholder Returns
532482 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | -0.9% | 1.6% | 0.009% |
1Y | -6.2% | 10.6% | -1.1% |
Return vs Industry: 532482 underperformed the Indian Pharmaceuticals industry which returned 10.6% over the past year.
Return vs Market: 532482 underperformed the Indian Market which returned -1.1% over the past year.
Price Volatility
532482 volatility | |
---|---|
532482 Average Weekly Movement | 4.5% |
Pharmaceuticals Industry Average Movement | 5.9% |
Market Average Movement | 6.0% |
10% most volatile stocks in IN Market | 8.7% |
10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 532482 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 532482's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1984 | 4,057 | Krishna Chigurupati | www.granulesindia.com |
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology.
Granules India Limited Fundamentals Summary
532482 fundamental statistics | |
---|---|
Market cap | ₹119.51b |
Earnings (TTM) | ₹5.02b |
Revenue (TTM) | ₹44.82b |
Is 532482 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
532482 income statement (TTM) | |
---|---|
Revenue | ₹44.82b |
Cost of Revenue | ₹17.26b |
Gross Profit | ₹27.56b |
Other Expenses | ₹22.54b |
Earnings | ₹5.02b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
Earnings per share (EPS) | 20.68 |
Gross Margin | 61.49% |
Net Profit Margin | 11.19% |
Debt/Equity Ratio | 34.6% |
How did 532482 perform over the long term?
See historical performance and comparisonDividends
Does 532482 pay a reliable dividends?
See 532482 dividend history and benchmarksGranules India dividend dates | |
---|---|
Ex Dividend Date | Jul 31 2025 |
Dividend Pay Date | Sep 06 2025 |
Days until Ex dividend | 24 days |
Days until Dividend pay date | 61 days |
Does 532482 pay a reliable dividends?
See 532482 dividend history and benchmarksCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/07/06 22:15 |
End of Day Share Price | 2025/07/04 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Granules India Limited is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Harith Ahamed | Avendus Spark |
Vijayaraghavan Swaminathan | Avendus Spark |
Cyndrella Carvalho | Centrum Broking Limited |